Global Primary Sclerosing Cholangitis (PSC) Market is poised to surpass US$ 314.26 Million by 2033, as projected by FMI

Primary Sclerosing Cholangitis (PSC) Market

The global primary sclerosing cholangitis (PSC) market is expected to be worth US$ 151.07 million in 2023. Because of rising alcohol consumption, the overall demand for Primary Sclerosing Cholangitis (PSC) is expected to grow at a CAGR of 7.6% between 2023 and 2033, totaling around US$ 314.26 Million by 2033.

The Primary Sclerosing Cholangitis (PSC) market is expected to grow during the analysis period, owing to factors such as an increase in the incidence of liver diseases and an increase in alcohol consumption, according to Future Market Insights. The global incidence of liver disease in 2016 was 3.9 million, according to the Centers for Disease Control and Prevention. According to the World Health Organization (WHO), alcohol consumption is increasing the prevalence of liver cirrhosis in European countries. Furthermore, rising awareness campaigns and increased R&D investment for the development of new drug molecules are expected to drive the primary sclerosing cholangitis market during the forecast period.

Request A Sample Copy Of This Research Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-16176

The rising prevalence of disorders associated with PSC, such as liver cancer and inflammatory bowel disease, is another factor that is expected to fuel therapeutic acceptance of effective pharmaceuticals to treat the condition, accelerating market growth. According to the World Journal of Gastroenterology, inflammatory bowel disease (IBD) is found in 50-80% of PSC patients, with ulcerative colitis (UC) accounting for 80-90 percent of these cases.

Key Takeaways:

The PSC market is expected to grow significantly over the next decade, driven by factors such as the increasing prevalence of PSC, rising awareness of the disease, and growing R&D investment.

The ursodiol drug type segment is expected to account for the largest share of the PSC market during the forecast period. This is due to the fact that ursodiol is the only FDA-approved drug for the treatment of PSC.

The off-label drugs segment is expected to account for the largest share of the PSC market based on treatment type during the forecast period. This is due to the fact that there are a number of off-label drugs that are used to treat PSC, such as budesonide and obeticholic acid.

North America is expected to account for the largest share of the PSC market based on region during the forecast period. This is due to the high prevalence of PSC in North America and the availability of advanced treatment options.

Our Analyst Is Available To Help You With Any Inquiries You May Have! https://www.futuremarketinsights.com/ask-question/rep-gb-16176

Primary Sclerosing Cholangitis (PSC) Market: Competition Analysis

The FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Primary Sclerosing Cholangitis (PSC) market. Competitive information detailed in the Primary Sclerosing Cholangitis (PSC) market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Primary Sclerosing Cholangitis (PSC) market report.

Key players covered in the report include:

• Acorda Therapeutics, Inc.
• Gilead Sciences, Inc.
• NGM Biopharmaceuticals, Inc.
• Intercept Pharmaceuticals, Inc.
• Dr. Falk Pharma GmbH
• Allergan Plc.
• Shire Plc.
• Durect Corporation
• Conatus Pharmaceuticals, Inc.
• Sirnaomics, Inc.
• Shenzhen HighTide Biopharmaceutical Ltd

Get a Customized Scope to Match Your Need Ask an Expert! https://www.futuremarketinsights.com/customization-available/rep-gb-16176

Key Segments Covered in the Primary Sclerosing Cholangitis (PSC) Industry Analysis:

Primary Sclerosing Cholangitis (PSC) Market by Drug:

• BTT1023
• GS-9674
• NGM282
• OCA
• Cenicriviroc
• LUM001
• DUR928
• norUDCA
• HTD1801
• IDN-7314
• STP705

Primary Sclerosing Cholangitis (PSC) Market by Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube